Genasense Phase III Trial In Multiple Myeloma Fails
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta says it will analyze the trial data “in considerably more detail before making decisions regarding the Genasense program in myeloma.” News of the failed trial comes on the heels of a separate Phase III study of oblimersen in chronic lymphocytic leukemia that met its primary endpoint but failed to show a survival benefit.
You may also be interested in...
Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense
Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.
Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense
Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.
Genasense Gets Second Chance As Genta Completes Chronic Leukemia NDA
Genta hopes confirmatory trial to support accelerated approval will use different regimen combining Genasense with Rituxan and chemotherapy.